Immunological And Molecular Basis Of Anaphylaxis Caused By Peanut And Tree Nut Allergy
Funder
National Health and Medical Research Council
Funding Amount
$195,691.00
Summary
An allergy to nuts is estimated to affect 1% of the population and peanuts are the major cause of fatal food-induced anaphylaxis. Five deaths occurred in the UK in 1993 which attracted media attention to the gravity of this problem. Proteins in the nut trigger a massive immunological reaction that causes the body to go into anaphylactic shock in which all the major body systems shut down. Nut allergy usually presents in infancy and persists indefinitely. As nuts are used in a wider and less visi ....An allergy to nuts is estimated to affect 1% of the population and peanuts are the major cause of fatal food-induced anaphylaxis. Five deaths occurred in the UK in 1993 which attracted media attention to the gravity of this problem. Proteins in the nut trigger a massive immunological reaction that causes the body to go into anaphylactic shock in which all the major body systems shut down. Nut allergy usually presents in infancy and persists indefinitely. As nuts are used in a wider and less visible range of food products, sensitisation is increasing and occurring earlier. It has been proposed, wrongly, that peanut (groundnut) allergic patients do not suffer from allergy to tree nuts (hazel, almond, Brazil, walnut). However a British survey of 1250 patients suffering from peanut anaphylaxis revealed that 50% of people with peanut allergy are also allergic to other nuts confirming our own clinical observations. At present, unlike insect venom allergy, grass pollen allergy and house dust mite allergy, there is no preventative treatment available. We plan to explore peanut allergy and investigate cross-reactivity between peanuts and major tree nuts to attempt to identify an allergen(s) that could explain the molecular nature of the allergy and offer approaches to immunotherapy. This information is necessary if we are to achieve safe and effective allergy shots for patients with this life long and life-threatening allergy as well as assisting in the development of better diagnosticRead moreRead less
Mimotopes For The Investigation And Therapy Of Allergic Disease
Funder
National Health and Medical Research Council
Funding Amount
$203,296.00
Summary
10% of children now use regular asthma medication. The current treatments dampen allergic inflammation but 25% of asthmatic children, all under high medication, need multiple visits to the doctor, emergency treatment or hospitalisation,. Immunotherapy has, since 1911, used repeated injections of allergens. The end result has often been successful and lasting but the response has been unpredictable and requires years of multi-injection treatment. The challenge is to develop effective, applicable ....10% of children now use regular asthma medication. The current treatments dampen allergic inflammation but 25% of asthmatic children, all under high medication, need multiple visits to the doctor, emergency treatment or hospitalisation,. Immunotherapy has, since 1911, used repeated injections of allergens. The end result has often been successful and lasting but the response has been unpredictable and requires years of multi-injection treatment. The challenge is to develop effective, applicable immunotherapy which, like vaccines use few injections. Mimotopes provide a new opportunity. Studying the parts of the allergens recognized by the immune system (epitopes) can reveal important phenomena undetectable with whole allergens; and single epitopes may be a powerful avenue to effective immunotherapy. The therapy can be targeted to a selected arm of the immune system for maximal effect and the immediate side effects induced by cross linking antibodies with two epitopes can be avoided. Allergens interact with two types of lymphocyte, the T and B cells. T-cell epitopes can be easily studied because they comprise short regions of proteins which can be synthesized. B-cell (and antibody) epitopes are shapes formed by the interaction of several parts of a protein which cannot be represented by a simple sequence. The mimotope technology uses random peptides to obtain a shape which mimics the B-cell epitope. Here mimotopes will be produced and used to study the common specificities recognized in allergic responses to house dust mite allergens to develop new types of therapy. Importantly recent information shows that B-cell epitopes can be used to modify both T and B-cell function.Read moreRead less